Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Artikel in diesem Bereich werden auf Englisch angezeigt.
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Trade News am 2026-10-02 zum Markt: Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. Primärquelle: Original bei CNBC Top News (cnbc.com).